Provider Briefing: Airsupra Availability in 2026

Airsupra (Albuterol 90 mcg/Budesonide 80 mcg per actuation) has generated significant interest since its FDA approval in January 2023 as the first rescue inhaler combining a short-acting beta2-agonist with an inhaled corticosteroid. If you're prescribing it — or considering it — this briefing covers what you need to know about current availability, coverage challenges, and tools to help your patients access it.

Current Shortage Status

As of March 2026, Airsupra is not on the FDA's drug shortage list. AstraZeneca continues to manufacture and distribute the product without reported supply interruptions. However, many patients report difficulty finding it at retail pharmacies.

The access challenges are driven by economic and formulary factors rather than manufacturing constraints:

• High list price ($503.93 per inhaler as of January 2026) discourages proactive pharmacy stocking
• Brand-name-only status with no generic alternative
• Inconsistent formulary placement across commercial and Medicare Part D plans
• Prior authorization and step therapy requirements that reduce fill rates

In practice, this creates a "functional availability gap" — the product exists in the supply chain, but patients face real barriers to obtaining it.

Timeline: From Approval to Today

• January 2023: FDA approval of Airsupra for as-needed treatment or prevention of bronchoconstriction and reduction of exacerbation risk in adults with asthma
• Mid-2023: Commercial launch by AstraZeneca with SUPRA Savings Card program
• 2024: Gradual formulary uptake; many plans added Airsupra but with prior authorization requirements
• September 2025: Updated prescribing information reflecting statistically significant severe exacerbation risk reduction in mild asthma compared to Albuterol alone
• 2026: Expanding but still incomplete insurance coverage; no generic on the horizon

Prescribing Implications

The 2025 label update strengthened the clinical rationale for Airsupra, particularly in mild asthma where patients may rely exclusively on rescue inhalers. Key clinical considerations:

Guideline Alignment

Major asthma guidelines, including updates from GINA (Global Initiative for Asthma), increasingly recommend ICS-containing reliever therapy over SABA-alone rescue. Airsupra aligns directly with this recommendation as a fixed-dose ICS/SABA combination designed for as-needed use.

Patient Selection

Airsupra is particularly well-suited for:

• Patients with mild asthma who use rescue inhalers frequently but are non-adherent to daily controllers
• Patients who prefer a single rescue inhaler with anti-inflammatory benefit
• Patients experiencing frequent exacerbations despite SABA-only rescue use

It is not intended to replace daily maintenance therapy in patients with moderate-to-severe asthma who are well-controlled on their current regimen.

Important Safety Considerations

For a complete side effect profile, refer to the Airsupra side effects guide. Key points for prescribers:

• Maximum dose: 6 doses (12 inhalations) per 24 hours
• Common adverse reactions (≥1%): headache, oral candidiasis, cough, dysphonia
• Caution with strong CYP3A4 inhibitors (Ketoconazole, Ritonavir, Itraconazole, etc.) due to increased systemic Budesonide exposure
• Caution with beta-blockers, MAO inhibitors, tricyclic antidepressants, and non-potassium-sparing diuretics
• Not approved for patients under 18

For drug interaction details, see our Airsupra drug interactions reference.

Availability Picture

The practical availability landscape in 2026:

• Chain pharmacies: Inconsistent stocking. Automated inventory systems may not flag Airsupra in areas with low prescription volume. Patients often hear "we don't carry it."
• Independent pharmacies: More willing to order for individual patients. Typically available within 1-2 business days through wholesale channels.
• Mail-order pharmacies: Generally available for patients with insurance coverage. May be the most reliable fulfillment channel.
• Specialty pharmacies: Not required — Airsupra is available through standard pharmacy distribution.

Cost and Access Considerations

Cost remains the primary access barrier. Here's the landscape your patients are navigating:

• List price: $503.93 per inhaler
• Cash price range: $479–$737 depending on pharmacy
• Coupon card prices: ~$426 (SingleCare), ~$479 (GoodRx)
• SUPRA Savings Card: $0 copay for eligible commercially insured patients
• AZ&Me Patient Assistance: Free medication for qualifying uninsured/Medicare patients

For patients struggling with cost, the savings programs can make a meaningful difference. However, patients on government insurance (Medicare, Medicaid, VA, TriCare) are not eligible for the SUPRA Savings Card and must rely on formulary coverage or the AZ&Me program.

A comprehensive patient-facing resource on cost is available at how to save money on Airsupra.

Tools and Resources for Your Practice

Several tools can help streamline patient access to Airsupra:

Medfinder for Providers

Medfinder allows you to check real-time pharmacy availability for Airsupra in your patient's area. You can use it at the point of prescribing to direct patients to pharmacies that currently have it in stock, reducing fill failures and patient frustration.

Prior Authorization Support

When submitting prior authorization, highlight:

• The September 2025 label update showing reduced severe exacerbations vs. Albuterol alone
• Patient history of exacerbations despite SABA-only rescue
• Non-adherence to separate controller therapy
• GINA guideline alignment recommending ICS-containing reliever therapy

AstraZeneca Provider Resources

AstraZeneca offers provider-facing materials at airsuprahcp.com, including formulary status tools, prior authorization support, and savings program enrollment assistance.

Alternative Prescribing Strategies

When Airsupra is not accessible, consider these alternatives:

• MART with Symbicort/Breyna: Budesonide/Formoterol used as both controller and rescue. Generic Breyna offers cost advantages ($150–$250).
• SABA + separate ICS controller: Standard Albuterol rescue plus daily inhaled corticosteroid. Most affordable approach.
• Levalbuterol (Xopenex): For patients with Albuterol-related cardiovascular side effects.

For a patient-facing comparison, refer them to alternatives to Airsupra.

Looking Ahead

Several trends suggest improving access over the next 12-18 months:

• Expanding formulary coverage as clinical evidence accumulates
• The 2025 label update providing stronger prior authorization justification
• Growing guideline support for ICS-containing rescue approaches
• Increasing prescriber and pharmacist familiarity

However, the absence of a generic alternative means cost will remain a significant barrier for the foreseeable future.

Final Thoughts

Airsupra represents a meaningful advancement in asthma rescue therapy, but its clinical value is only realized when patients can actually access it. Understanding the availability landscape and proactively addressing coverage and cost barriers can help ensure your patients benefit from this therapy.

Use Medfinder for Providers to check real-time availability, direct patients to savings programs, and consider alternative strategies when access barriers prove insurmountable.

For a comprehensive medication overview to share with patients, see what is Airsupra: uses, dosage, and what you need to know.